Atherogenicity of triglyceride-rich lipoproteins

American Journal of Cardiology

Volumn 81, Issue 4 A, 1998, Pages 13B-17B

  Krauss, Ronald M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ANGIOCARDIOGRAPHY; ATHEROGENESIS; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; ECHOGRAPHY; HUMAN; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; PRIORITY JOURNAL;

EID: 0032567917     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(98)00032-0     Document Type: Conference Paper

References (35)

1. Triglyceride, high density lipoprotein, and coronary heart disease. NIH Consensus Development Conference Consensus Statement 1992, Feb 26-28, 1992.
2. Krauss RM. Physical heterogeneity of apolipoprotein B-containing lipoproteins. In: Lippel K, ed. Proceedings of the Workshop on Lipoprotein Heterogeneity. Washington, DC: US Govt. Printing Office, 1987:15-21. NIH Publication No. 87-2646.
3. Lindgren FT, Elliott HA, Gofman JW. The ultracentrifugal characterization and isolation of human blood lipids and lipoproteins, with applications to the study of atherosclerosis. J Phys Colloid Chem 1951;55:80-93.
4. Lindgren FT, Jensen LC, Hatch FT. The isolation and quantitative analysis of serum lipoproteins. In: Nelson GJ, ed. Blood Lipids and Lipoproteins: Quantitation, Composition, and Metabolism. New York: John Wiley and Sons, 1972: 181-274.
5. Alaupovic P. Apolipoprotein composition as the basis for classifying plasma lipoproteins. Prog Lipid Res 1991;30:105-138.
6. Gofman JW, Lindgren F, Elliott H, Mantz W, Hewitt J, Strisower B, Herring V, Lyon TP. The role of lipids and lipoproteins in atherosclerosis. Science 1950;111:166-171.
7. Gofman JW, Young W, Tandy R. Ischemic heart disease, atherosclerosis, and longevity. Circulation 1966;34:679-697.
8. Steiner G, Schwartz L, Shumak S, Poapst M. The association of increased levels of intermediate density lipoproteins with smoking and coronary heart disease. Circulation 1987;75:124-130.
9. Krauss RM, Lindgren FT, Williams PT, Kelsey SF, Brensike J, Vranizan K, Detre KM, Levy RI. Intermediate-density lipoproteins and progression of coronary artery disease in hypercholesterolaemic men. Lancet 1987;ii:62-66.
10. Phillips NR, Waters D, Havel RJ. Plasma lipoproteins and progression of coronary artery disease evaluated by angiography and clinical events. Circulation 1993;88:2762-2770.
11. Mack WJ, Krauss RM, Hodis HN. Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS) - Treatment effects and relation to coronary angiographic progression. Arterioscler Thromb Vasc Biol 1996;16:697-704.
12. Hodis HN, Mack WJ, Dunn M, Liu CR, Selzer RH, Krauss RM. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 1997;95:2022-2026.
13. Patsch JR, Miesenböck G, Hopferwieser T, Mühlberger V, Knapp E, Dunn JK, Gotto AM, Jr, Patsch W. Relation of triglyceride metabolism and coronary artery disease: studies in the postprandial state. Arterioscler Thromb Vasc Biol 1992;12:1336-1345.
14. Sharrett AR, Chambless LE, Heiss G, Paton CC, Patsch W. Association of postprandial triglyceride and retinyl palmitate responses with asymptomatic carotid artery atherosclerosis in middle-aged men and women - The Atherosclerosis Risk in Communities (ARIC) study. Arterioscler Thromb Vasc Biol 1995;15: 2122-2129.
15. Ginsberg HN, Jones J, Blaner WS, Thomas A, Karmally W, Fields L, Blood D, Begg MD. Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. Arterioscler Thromb Vasc Biol 1995; 15:1829-1838.
16. Simons LA, Dwyer T, Simons J, Bernstein L, Mock P, Poonia NS, Balasubramaniam S, Baron D, Branson J, Morgan J, Roy P. Chylomicrons and chylomicron remnants in coronary artery disease: a case-control study. Atherosclerosis 1987;65:181-189.
17. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994; 106:83-97.
18. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutation in the lipoprotein lipase gene. N Engl J Med 1996;335(12):848-854.
19. Rapp JH, Lespine A, Hamilton RL, Colyvas N, Chaumeton AH, Tweedie-Hardman J, Kottie L, Kunitake ST, Havel RJ, Kane JP. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler Thromb Vasc Biol 1994;14:1767-1774.
20. Chung BH, Segrest JP. Cytotoxicity of remnants of triglyceride-rich lipoproteins: an atherogenic insult? Adv Exp Med Biol 1991;285:341-351.
21. Chung BH, Tallis G, Yalamoori V, Anantharamaiah GM, Segrest JP. Liposome-like particles isolated from human atherosclerotic plaques are structurally and compositionally similar to surface remnants of triglyceride-rich lipoproteins. Arterioscler Thromb 1994;14:622-635.
22. Nordestgaard BG. The vascular endothelial barrier - selective retention of lipoproteins. Curr Opin Lipidol 1996;7:269-273.
23. Gianturco SH, Bradley WA. Lipoprotein mediated cellular mechanisms for atherosclerosis in hypertriglyceridemia. Semin Thromb Hemost 1987;14:164-168.
24. Nordestgaard BG, Agerholm-Larsen B, Mortensen A, Hansen BF, Hansen JF, Ibsen P, Kjeldsen K. Intermediate density lipoprotein cholesterol as the best lipoprotein predictor of atherosclerosis severity in the Watanabe Heritable Hyperlipidemic rabbit. Atherosclerosis 1997;132:119-122.
25. Masucci-Magoulas L, Goldberg IJ, Bisgaier CL, Serajuddin H, Francone OL, Breslow JL, Tall AR. A mouse model with features of familial combined hyperlipidemia. Science 1997;275:391-394.
26. Grundy SM. Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 1997;95:1-4.
27. Reaven GM. Syndrome X: 6 years later. J Intern Med 1994;736:13-22.
28. Blankenhorn DH, Alaupovic P, Wickham E, Chin HP, Azen SP. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts: lipid and nonlipid factors. Circulation 1990;81:470-476.
29. Hodis HN, Mack WJ, Azen SP, Alaupovic P, Pogoda JM, LaBree L, Hemphill LC, Kramsch DM, Blankenhorn DH. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild and moderate/severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin. Circulation 1994;90:42-49.
30. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype: a proposed genetic marker for coronary heart disease risk. Circulation 1990;82:495-506.
31. Krauss RM, Hellerstein MK, Neese RA, Blanche PJ, La Belle MA, Shames DM. Altered metabolism of large low density lipoproteins in subjects with a predominance of small low density lipoproteins. (Abstr.) Circulation 1995;92:I-102.
32. Krauss RM. Relationship of intermediate and low-density lipoprotein subspecies to risk of coronary artery disease. Am Heart J 1987;113:578-582.
33. Bjornheden T, Babyi A, Bondjers G, Wiklund O. Accumulation of lipoprotein fractions and subfractions in the arterial wall, determined in an in vitro perfusion system. Atherosclerosis 1996;123:43-56.
34. Anber V, Griffin BA, McConnell M, Packard CJ, Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis 1996;124: 261-271.
35. Tribble DL. Lipoprotein oxidation in dyslipidemia: insights into general mechanisms affecting lipoprotein oxidative behavior. Curr Opin Lipidol 1995;6: 196-208.